Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3LRAC)

• Drug Name: XL092 Drug Info
• Synonyms: SCHEMBL21200856; NSC828252; XL-092; NSC-828252; 2367004-54-2

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 139350422
  TTD Drug ID: DM3LRAC

Molecule-Related Drug Atlas

Drug(s) Targeting Vascular endothelial growth factor receptor (VEGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Intedanib	DMSTA36	Colorectal cancer	2B91.Z	Approved	[3]
Fruquintinib	DMHOSCQ	Colorectal cancer	2B91.Z	Approved	[4]
Sulfatinib	DMPOTM4	Neuroendocrine cancer	2B72.1	Phase 3	[4]
KH-902	DM8VO16	Diabetic macular edema	9B71.02	Phase 3	[5]
ABP 938	DM00ACQ	Neovascular age-related macular degeneration	9B78.3Z	Phase 3	[6]
XL-820	DMMHX9K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[7]
BAY-57-9352	DMVA5NS	Gastric adenocarcinoma	2B72	Phase 2	[8]
X-82	DMW1NKO	Age-related macular degeneration	9B75.0	Phase 2	[4]
Vorolanib	DMIM1U9	Non-small-cell lung cancer	2C25	Phase 2	[9]
BFH-772	DMVUX1C	Psoriasis vulgaris	EA90	Phase 2	[10]

Drug(s) Targeting Proto-oncogene c-Met (MET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[11]
Cabozantinib	DMIYDT4	Medullary thyroid gland carcinoma		Approved	[12]
Amivantamab	DMZ7AMY	Non-small-cell lung cancer	2C25	Approved	[13]
Capmatinib	DMYCXKL	Non-small-cell lung cancer	2C25.Y	Approved	[14]
Tepotinib	DMUQ0E8	Non-small-cell lung cancer	2C25	Approved	[15]
RG3638	DMTQJE0	Gastric adenocarcinoma	2B72	Phase 3	[16]
Savolitinib	DMALFKX	Renal cell carcinoma	2C90	Phase 3	[4]
Beperminogene perplasmid	DM6RWBN	Critical limb ischemia	BD4Y	Phase 3	[17]
Tivantinib	DMNVP8Q	Hepatocellular carcinoma	2C12.02	Phase 3	[18]
MGCD516	DM752PU	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Proto-oncogene c-Met (MET)	TTNDSF4	MET_HUMAN	Inhibitor	[2]
Vascular endothelial growth factor receptor (VEGFR)	TTVJ1D8	NOUNIPROTAC	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT03845166) A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Exelixis.
• [3] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats. Diabetes Obes Metab. 2012 Jul;14(7):644-53.
• [6] Clinical pipeline report, company report or official report of Amgen
• [7] National Cancer Institute Drug Dictionary (drug id 452042).
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res. 2021 Feb 28;33(1):103-114.
• [10] CA patent application no. 841416, Method of selecting therapeutic indications.
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [12] Clinical pipeline report, company report or official report of Exelixis (2011).
• [13] Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [15] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [16] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
• [17] Beperminogene perplasmid for the treatment of critical limb ischemia. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1145-56.
• [18] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7948).